Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia

作者：Chi Benjamin H; Cantrell Ronald A; Zulu Isaac; Mulenga Lloyd B; Levy Jens W; Tambatamba Bushimbwa C; Reid Stewart; Mwango Albert; Mwinga Alwyn; Bulterys Marc; Saag Michael S; Stringer Jeffrey S A

来源：International Journal of Epidemiology, 2009, 38(3): 746-756.

DOI：10.1093/ije/dyp004

• HIV
• adherence
• medication possession ratio
• mortality
• survival
• antiretroviral therapy
• Africa
• Zambia

Background High-level adherence to antiretroviral therapy (ART) is associated with favourable patient outcomes. In resource-constrained settings, however, there are few validated measures. We examined the correlation between clinical outcomes and the medication possession ratio (MPR), a pharmacy-based measure of adherence.
Methods We analysed data from a large programmatic cohort across 18 primary care centres providing ART in Lusaka, Zambia. Patients were stratified into three categories based on MPR-calculated adherence over the first 12 months: optimal (>= 95%), suboptimal (80-94%) and poor (<80%).
Results Overall, 27 115 treatment-naive adults initiated and continued ART for >= 12 months: 17060 (62.9%) demonstrated optimal adherence, 7682 (28.3%) had suboptimal adherence and 2373 (8.8%) had poor adherence. When compared with those with optimal adherence, post-12-month mortality risk was similar among patients with suboptimal adherence [adjusted hazard ratio (AHR) = 1.0; 95% CI: 0.9-1.2] but higher in patients with poor adherence (AHR = 1.7; 95% CI: 1.4-2.2). Those <80% MPR also appeared to have an attenuated CD4 response at 18 months (185 cells/mu l vs 217 cells/mu l; P<0.001), 24 months (213 cells/mu l vs 246 cells/mu l; P<0.001), 30 months (226 cells/mu l vs 261 cells/mu l; P<0.001) and 36 months (245 cells/mu l vs 275 cells/mu l; P<0.01) when compared with those above this threshold.
Conclusions MPR was predictive of clinical outcomes and immunologic response in this large public sector antiretroviral treatment program. This marker may have a role in guiding programmatic monitoring and clinical care in resource-constrained settings.

• 出版日期2009-6